Ocrevus 300 MG/10 ML vial 10ML
Ended Awarded Last action
- Contract number
- SPE2DR26F1AG7
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,638
Award facts
- Contract value 100% obligated
- $25,637.70 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., received a $25,637.70 firm fixed-price delivery order from the Defense Logistics Agency on January 21, 2026, for Ocrevus 300 mg/10 ml vials. The contract, which carries an ultimate completion date of February 11, 2026, represents a non-competitive award under an existing indefinite delivery contract vehicle. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order exemplifies the ongoing pharmaceutical supply relationship between the Defense Logistics Agency and Amerisourcebergen, which holds a substantial $999,999,999 indefinite delivery contract through December 2026 serving as the primary vehicle for delivering pharmaceutical products and medical supplies to support military healthcare programs globally.
Ocrevus (ocrelizumab) is a monoclonal antibody used in the treatment of multiple sclerosis and is classified as a specialty pharmaceutical product. This order demonstrates the breadth of Amerisourcebergen's pharmaceutical portfolio for federal military medical procurement, encompassing specialty medications alongside generic and brand-name drugs. The Defense Logistics Agency Medical Supply Chain relies on such delivery orders to maintain inventory of critical therapeutic medications across multiple medical facilities serving active-duty personnel, military veterans, and other Department of Defense beneficiaries.
Quick answers
Who was awarded contract SPE2DR26F1AG7?
SPE2DR26F1AG7 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 21, 2026.
How much is contract SPE2DR26F1AG7 worth?
The government has obligated $25,638 on SPE2DR26F1AG7.
Is contract SPE2DR26F1AG7 an order under another contract?
Yes. SPE2DR26F1AG7 is a delivery order under SPE2DR25D1205, an indefinite delivery contract.
Was contract SPE2DR26F1AG7 competed?
The extent of competition for SPE2DR26F1AG7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award